AAIC 2025 Abstract
Returning pTau‐217 results: Methods from the Evaluation of Self‐Mediated Alternatives for Risk Testing Education and Return of Results (eSMARTER) study
By Claire M. Erickson, Kristin A. Harkins, Elisabeth Wood, Show 6 more authorsJessica B. S. Langbaum
Trial in peopleInterventions
Abstract
Background: Though not yet part of routine care, Alzheimer's disease (AD) blood biomarkers are poised for broad use in diagnosis and management and already used in clinical trials to determine participant eligibility.
